Market News
- Coya Therapeutics CEO Discusses Company’s Treatment Pipelineby OncLive articles on April 26, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at the organization’s pipeline.
- FDA Approves Label Update for Gilead’s Biktarvy to Include Pregnant Adults With HIVby OncLive articles on April 26, 2024
Approval update comes as a result of findings from Study 5310, which addressed Biktarvy’s pharmacokinetics, safety, and efficacy during pregnancy and postpartum periods in patients with HIV.
- FDA Approves Pfizer’s Beqvez for the Treatment of Adults with Moderate to Severe Hemophilia Bby OncLive articles on April 26, 2024
Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.
- AbbVie tries to reassure investors on Humira biosimilar threatby Jonathan Gardner (BioPharma Dive – Latest News) on April 26, 2024
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
- Going Beyond Visuals to Connect with Diverse Audiencesby OncLive articles on April 26, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers can utilize to connect with diverse audiences on a deeper level
- Pfizer hemophilia gene therapy arrives in US to uncertain futureby Ben Fidler (BioPharma Dive – Latest News) on April 26, 2024
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
- The privileged status of orphan medicines in Germanyby Alex Watt (Pharmaceutical Technology) on April 26, 2024
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.
- Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talksby GlobalData Healthcare (Pharmaceutical Technology) on April 26, 2024
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.
- Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapyby Phalguni Deswal (Pharmaceutical Technology) on April 26, 2024
The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
- Merck’s net income for Q1 2024 increases by 69% to $4.76bnby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Merck has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in Q1 2024, a 69% rise from $2.82bn in the same period last year.
- Multiply Labs and GenScript partner on cell isolation automationby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing.
- Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & moreby OncLive articles on April 26, 2024
The latest news for pharma industry insiders.
- BioAro Announces Real Time DNA Decoding Technologyby OncLive articles on April 26, 2024
PanOmiQ is referred to as the fasted technology of its kind by the company.
- Solving the First Mile Problem: Q&A with Mark Meltonby OncLive articles on April 26, 2024
Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
- CVS Health Announces New Work Force Development and Community Center in Louisianaby OncLive articles on April 26, 2024
The center will offer local residents with opportunities and training to enter the pharmacy work force.
- Regeneron and Mammoth team up to develop gene editing therapiesby Archana Rani (Pharmaceutical Technology) on April 26, 2024
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
- AstraZeneca posts $2.18bn profit after tax in Q1 2024by Archana Rani (Pharmaceutical Technology) on April 26, 2024
AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year.
- Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovyby Justine Ra (Pharmaceutical Technology) on April 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
- AstraZeneca’s earnings surprise investors as cancer drugs fuel growthby Jonathan Gardner (BioPharma Dive – Latest News) on April 25, 2024
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
- Novartis, Medicines for Malaria Venture Release Positive Results from Phase II/III Trial of Coartem for Infants with Malariaby OncLive articles on April 25, 2024
Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.